Medexus Pharmaceuticals Inc
TSX:MDP

Watchlist Manager
Medexus Pharmaceuticals Inc Logo
Medexus Pharmaceuticals Inc
TSX:MDP
Watchlist
Price: 2.66 CAD Market Closed
Market Cap: 86.2m CAD

MDP's latest stock split occurred on Dec 19, 2018

The company executed a 1-for-15 stock split, meaning that for every 15 shares held, investors received 1 new share.

Before the split, MDP traded at 0.3 per share. Afterward, the share price was about 5.

The adjusted shares began trading on Dec 19, 2018. This was MDP's 4th stock split, following the previous one in Mar 18, 1997.

Last Splits:
Dec 19, 2018
1-for-15
Mar 18, 1997
2-for-1
Mar 17, 1995
2-for-1
Aug 12, 1983
3-for-1
Pre-Split Price
4.5 0.3
Post-Split Price
5
Before
After
Last Splits:
Dec 19, 2018
1-for-15
Mar 18, 1997
2-for-1
Mar 17, 1995
2-for-1
Aug 12, 1983
3-for-1

Medexus Pharmaceuticals Inc
Stock Splits History

MDP Stock Splits Timeline
Dec 19, 2018
Dec 19, 2018
Split 1-for-15
/0.066666666666667
Pre-Split Price
4.5 0.3
Post-Split Price
5
Before
After
Mar 18, 1997
Mar 18, 1997
Split 2-for-1
x2
Pre-Split Price
N/A
Post-Split Price
7.95
Before
After
Mar 17, 1995
Mar 17, 1995
Split 2-for-1
x2
Pre-Split Price
N/A
Post-Split Price
7.95
Before
After
Aug 12, 1983
Aug 12, 1983
Split 3-for-1
x3
Pre-Split Price
N/A
Post-Split Price
7.95
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
Dec 29, 2025
Ise Chemicals Corp
OTC:ICHMF
10-for-1
x10
32.808 32.808 USD N/A
Dec 29, 2025
Bridgestone Corp
OTC:BRDCF
2-for-1
x2
46.07 46.07 USD N/A
Dec 29, 2025
Ibiden Co Ltd
OTC:IBIDF
2-for-1
x2
81 81 USD N/A
Dec 29, 2025
Itochu Corp
OTC:ITOCF
5-for-1
x5
58.88 58.88 USD N/A
Dec 29, 2025
Sumitomo Realty & Development Co Ltd
OTC:SURDF
2-for-1
x2
51.129 51.129 USD N/A
Load More

Medexus Pharmaceuticals Inc
Glance View

Market Cap
86.2m CAD
Industry
Pharmaceuticals

Medexus Pharmaceuticals, Inc. operates as a pharmaceutical company, which provides healthcare products to Healthcare Professionals and patients and focuses on therapeutic areas of auto-immune disease and pediatrics. The company is headquartered in Bolton, Ontario and currently employs 79 full-time employees. The company went IPO on 2012-03-03. The firm is a North American focused, specialty pharmaceutical business that operates through two divisions: Medexus Pharma Canada and Medexus Pharma USA. Medexus Pharma Canada, a fully integrated commercial infrastructure focused on rheumatology, allergy, auto-immune disease, specialty oncology and pediatric diseases in Canada. Medexus Pharma USA, a fully integrated commercial infrastructure focused on rheumatology and auto-immune diseases in the United States (U.S). The firm is focused on the therapeutic areas of auto-immune disease, hematology, pediatrics, dermatology and allergy. The firm's products are Rasuvo and Metoject, a formulation of methotrexate (auto-pen and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases. The company also offers IXINITY, a medicine for use in patients 12 years of age or older with Hemophilia B and Rupall, an allergy medication.

MDP Intrinsic Value
HIDDEN
Show
Back to Top